INTRODUCTION
============

Chronic kidney disease (CKD) is a largely asymptomatic condition of diminished renal function.^[@b1]^ It has an estimated prevalence in England of 15% in people aged ≥35 years, and an estimated annual cost to the NHS of 1.4 billion GBP.^[@b2]^ CKD prevalence increases with age and it is independently associated with increased cardiovascular disease risk and all-cause mortality.^[@b3]^ Having CKD stage ≥3 is the leading risk factor for progression to end-stage renal disease (ESRD)^[@b4]^ and a strong predictor of hospitalisation.^[@b5]^ Globally, CKD mortality has increased by one-third over the last 10 years, accounting for 1.2 million deaths annually worldwide.^[@b6]^

International guidelines, such as those from the National Institute for Health and Care Excellence (NICE)^[@b7]^ and Kidney Disease: Improving Global Outcomes (KDIGO),^[@b8]^ recommend that people with CKD are identified early to address cardiovascular risk, slow CKD progression, and reduce the numbers reaching ESRD and associated costs.^[@b9]^ Many patients in primary care have CKD that is not formally recognised, and it is unclear whether this has any bearing on their prognosis.^[@b10]^

CKD is characterised by measures of renal function including increasing urinary albumin:creatinine ratio (ACR) or decreasing glomerular filtration rate (GFR), estimated from serum creatinine (eGFR). In line with recommendations from NICE^[@b7]^ and KDIGO,^[@b8]^ CKD is classified into stages based on eGFR and ACR cut-offs. [Figure 1](#fig1){ref-type="fig"}, adapted from KDIGO guidelines,^[@b8]^ shows the categories and increased risk of adverse outcomes as CKD stage increases. Many reports of CKD prevalence have only used a single measurement,^[@b11]^ which may have resulted in biased estimates.

![***Classification of chronic kidney disease (CKD) using glomerular filtration rate (GFR) and albumin:creatinine ratio (ACR).***\
***Adapted from KDIGO guidelines^[@b8]^ with permission from Elsevier. A1 = normal albuminuria. A2 = micro-albuminuria. A3 = macro-albuminuria. G = stage of CKD (1--5) by GFR category.***](bjgpApr-2020-70-693-e285-OA-1){#fig1}

Though CKD is usually asymptomatic until later stages of the disease (stage ≥4), earlier stages (1--3) are associated with increased mortality^[@b12]^ and cardiovascular risk.^[@b3]^ It may therefore be beneficial to establish efficient detection mechanisms for patients with early-stage CKD. Screening enables early detection, but mass screening of all age groups for kidney disease is expensive, of low yield, and not cost-effective.^[@b13]^ There is an age-related decline in renal function and UK data show that from age 60 years the prevalence of CKD stages 3--5 increases rapidly.^[@b14],[@b15]^ It may, therefore, be reasonable to consider screening systematically in this age group.

###### 

How this fits in

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Chronic kidney disease (CKD) is a largely asymptomatic condition with a reported prevalence of around 15% in England in people aged ≥35 years. Routine screening in older people may detect undiagnosed CKD. Using two measurements of serum creatinine and urinary albumin, this study found the prevalence was 18.2% for any-stage CKD and 13.9% in stages 3--5 in an older primary care population (aged ≥60 years). Screening using these two measurements identified that around 8% of older people were living with undiagnosed CKD.
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The Oxford Renal Longitudinal Cohort Study (OxRen) is a prospective observational longitudinal cohort study of a primary care population aged ≥60 years. The study was established by the University of Oxford in 2013 in the central region of the UK to answer important research questions around these uncertainties. The key objectives were to determine the prevalence, annual incidence, and progression of CKD in an older UK population to define the prevalence of selected risk factors and establish the distribution of estimated kidney function in patients detected by a targeted screening programme.^[@b16]^ This article reports estimates of the proportion of people with undiagnosed CKD, overall CKD prevalence, and characteristics from the OxRen study cohort.

METHOD
======

Participants aged ≥60 years were recruited in 13 primary care clinics across Oxfordshire, UK, over 44 months, from November 2013 to July 2017. Patients were excluded if they were unable to give informed consent, were terminally ill, had a previous solid organ transplant, or if the GP judged them to be unable to give consent. Eligible participants were invited to attend an initial visit where the study was explained and written informed consent was obtained.

Participants entered the OxRen CKD cohort either on the basis of an existing diagnosis of CKD in their GP records, or through screening. Screening visits involved a serum creatinine test to calculate eGFR and a urinary ACR test. Participants with no previous diagnosis of CKD attended a screening visit (A). If the screening result showed decreased renal function (eGFR \<65 ml/min/1.73 m^2^) or evidence of kidney damage (ACR ≥3 mg/mmol), the participant proceeded to a second screening visit (B) after a 3-month interval to have their CKD diagnosis confirmed. If after this visit, the participant had two abnormal results (eGFR \<60 ml/min/1.73 m^2^ or ACR ≥3 mg/mmol), they were classified as having CKD and invited to attend the baseline assessment visit at their GP practice.

If on the second occasion the eGFR and ACR did not fall within the criteria for CKD diagnosis, participants were still invited to the baseline assessment visit but classified as having borderline/transient decreased renal function providing their first result suggested CKD stage 1--5. Participants who had a borderline result in their first test and abnormal second test result were also classified as having borderline/transient decreased renal function and invited to attend a baseline assessment. All participants invited to the baseline assessment are hereafter called the CKD cohort ([Figure 2](#fig2){ref-type="fig"}).

![***Participant flow chart.***\
***^a^National Institute for Health and Care Excellence criteria for diagnosis of chronic kidney disease (CKD): ≥2 results at least 3 months apart. ^b^Estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73 m^2^, or eGFR \>60 ml/min/1.73 m^2^, and albumin:creatinine ratio (ACR) \>3 mg/mmol; at least one result must be from Screening A or Screening B.***](bjgpApr-2020-70-693-e285-OA-2){#fig2}

At the baseline assessment visit, data were collected on demographics, lifestyle, and medical history. Anthropometric and clinical measurements (blood pressure and pulse wave velocity) were made. Questionnaires were completed on diet, physical activity, cognitive function, and quality of life. Blood and urine samples were sent for immediate laboratory analysis, and additional blood and urine samples were collected and stored at −80°C for future genetic and protein testing.

All samples were processed across two laboratories using identical instrumentation and assay standardisation. Serum creatinine was measured using an isotope dilution mass spectrometry traceable method^[@b17]^ and eGFR was reported using the Modification of Diet in Renal Disease (MDRD) equation.^[@b18]^ The most recent test result was used for 12 participants where no results were available at the time of the test. The effect of these approximations on results was tested by re-analysing data excluding these participants from the analysis.

Data management and reporting
-----------------------------

Participants whose laboratory eGFR was reported as \>90 ml/min/1.73 m^2^ (*n* = 2) were designated to have eGFR of 91 ml/min/1.73 m^2^. Urinary albumin levels were approximated to 4.9 mg/L for 29 participants whose laboratory urinary albumin levels were reported as \<5 mg/L. These were excluded in a sensitivity analysis in two cases where this may have changed stage of CKD. CKD stage was reported for all participants. Results were tabulated for the full CKD cohort and stratified both by stage of CKD and how the participant entered the cohort (previous diagnosis, new diagnosis, or borderline/transient decreased renal function) to report prevalence and 95% confidence intervals (CIs).^[@b19],[@b20]^ The eGFR results and stage of CKD were also reported using the CKD Epidemiology Collaboration (CKD-EPI) equation, which is the global standard for estimating GFR for comparison purposes, and prevalence of reduced eGFR (\<60 ml/min/1.73 m^2^) was compared with MDRD across participant age.

All data management and analyses were carried out using Stata (version 14SE). Data are presented in tables and summarised as number and per cent, or mean and standard deviation (SD). For continuous variables that were non-normally distributed, the median and interquartile range (IQR) are reported.

Data sharing
------------

Requests to access OxRen data should be addressed to the corresponding authors.

Patient and public involvement
------------------------------

A patient representative sits on the Study Steering Committee that meets on a 6-monthly basis to assess the progress of participant recruitment and follow-up, to review and contribute to study materials, and to oversee the ethical and safe conduct of the research.

RESULTS
=======

In total, 8268 people were invited to participate in OxRen and 3207 were recruited (38.8% recruitment rate). Among recruited participants, 327 had CKD previously documented from GP records and 2880 attended screening visits. At screening, 534 (18.5%, 534/2880) had one or more positive tests for CKD (257 newly diagnosed, 277 borderline/transient decreased renal function). The resulting total of 861 participants (26.8% of those recruited) entered the CKD cohort and attended the baseline assessment. Overall, newly diagnosed CKD was 8.0% (257/3207) (95% CI = 7.1 to 9.0) and pre-existing CKD was 10.2% (327/3207) (95% CI = 9.2 to 11.3) giving CKD prevalence of 18.2% (584/3207) (95% CI = 16.9 to 19.6). Of the 584 with confirmed CKD, 44.0% were diagnosed through screening ([Figure 2](#fig2){ref-type="fig"}).

Characteristics of the 861 participants who attended a baseline study visit are shown in [Table 1](#table1){ref-type="table"}. Results are presented for all participants and stratified by whether they had existing CKD, newly diagnosed, or borderline/transient decreased renal function. Briefly, 54.4% were female, mean (SD) age was 74.0 (SD 6.9) years, mean BMI was 28.1 (SD 7.3) kg/m^2^, and 846 (98.3%) were white. Prevalence of hypertension was 59.3% and diabetes was 15.4%. These, and prevalence of other comorbidities, are presented for the full cohort and for different subgroups in [Tables 1](#table1){ref-type="table"} and [2](#table2){ref-type="table"}, and Supplementary Table S1.

###### 

Patient demographics stratified by screening data

  **Characteristics**                     **Full cohort (*N*= 861)**                    **Existing CKD (*N*= 327)**   **Newly diagnosed CKD (*N*= 257)**   **Borderline/transient decreased renal function (*N*= 277)**
  --------------------------------------- --------------------------------------------- ----------------------------- ------------------------------------ --------------------------------------------------------------
    CKD prevalence, % (95% CI)            18.2 (16.9 to 19.6)                           10.2 (9.2 to 11.3)            8.0 (7.1 to 9.0)                     ---
    Mean age, years (SD)                  74.0 (6.9)                                    75.4 (7.0)                    73.4 (6.5)                           72.7 (6.7)
    Female, *n* (%)                       468 (54.4)                                    183 (56.0)                    124 (48.2)                           161 (58.1)
    Mean weight, kg (SD)                  78.0 (17.1)                                   77.3 (16.1)                   80.2 (18.0)                          76.8 (17.4)
    Mean height, cm (SD)                  167.0 (10.5)                                  167.0 (10.2)                  167.8 (10.0)                         166.1 (11.2)
    Mean waist circumference, cm (SD)     97.0 (14.6)                                   97.0 (13.4)                   99.0 (15.2)                          95.0 (15.1)
    Mean hip circumference, cm (SD)       106.4 (10.7)                                  106.9 (10.3)                  107.0 (11.3)                         105.4 (10.4)
    Mean BMI, kg/m^2^ (SD)                28.1 (7.3)                                    27.6 (5.1)                    28.5 (6.4)                           28.2 (9.9)
                                                                                                                                                           
  **Ethnicity, *n* (%)**                                                                                                                                   
    White                                 846 (98.3)[^a^](#tfn1){ref-type="table-fn"}   323 (98.8)                    253 (98.4)                           271 (97.8)
    Other                                 14 (1.6)                                      4 (1.2)                       4 (1.6)                              6 (2.2)
                                                                                                                                                           
  **Educational status, *n* (%)**                                                                                                                          
    School up to 16 years                 483 (56.1)                                    183 (56.0)                    150 (58.4)                           150 (54.2)
    Sixth form school or college          174 (20.2)                                    57 (17.4)                     55 (21.4)                            62 (22.4)
    University or higher                  204 (23.7)                                    87 (26.6)                     52 (20.2)                            65 (23.5)
                                                                                                                                                           
  **Smoking status, *n* (%)**                                                                                                                              
    Never                                 466 (54.1)                                    171 (52.3)                    137 (53.3)                           158 (57.0)
    Former                                357 (41.5)                                    142 (43.4)                    111 (43.2)                           104 (37.5)
    Current                               38 (4.4)                                      14 (4.3)                      9 (3.5)                              15 (5.4)
                                                                                                                                                           
  **Alcohol use, units/week**                                                                                                                              
    None, *n* (%)                         252 (29.3)                                    85 (26.0)                     88 (34.2)                            79 (28.5)
    One or more, *n* (%)                  609 (70.7)                                    242 (74.0)                    169 (65.8)                           198 (71.5)
    Median (IQR)                          2 (0 to 8)                                    2 (0 to 7)                    2 (0 to 9)                           3 (0 to 10)
    Mean (SD)                             5.9 (8.7)                                     5.3 (8.0)                     6.1 (9.1)                            6.4 (9.0)
                                                                                                                                                           
  **Major comorbidities, *n* (%)**                                                                                                                         
    Hypertension                          511 (59.3)                                    213 (65.1)                    160 (62.3)                           138 (49.8)
    Diabetes                              133 (15.4)                                    71 (21.7)                     38 (14.8)                            24 (8.7)
    Ischaemic heart disease               145 (16.8)                                    62 (19.0)                     50 (19.5)                            33 (11.9)
    Heart failure                         39 (4.5)                                      19 (5.8)                      13 (5.1)                             7 (2.5)
    Atrial fibrillation                   110 (12.8)                                    50 (15.3)                     34 (13.2)                            26 (9.4)
    Cerebrovascular disease               73 (8.5)                                      36 (11.0)                     23 (8.9)                             14 (5.1)
    Peripheral vascular disease           29 (3.4)                                      9 (2.8)                       9 (3.5)                              11 (4.0)
                                                                                                                                                           
  **Systolic blood pressure, mmHg**                                                                                                                        
    Median (IQR)                          132 (120 to 144)                              130 (119 to 142)              135 (123 to 145)                     131 (121 to 145)
    Mean (SD)                             133 (18)                                      131 (17)                      135 (19)                             132 (18)
                                                                                                                                                           
  **Diastolic blood pressure, mmHg**                                                                                                                       
    Median (IQR)                          78 (71 to 84)                                 77 (70 to 82)                 79 (72 to 85)                        78 (71 to 84)
    Mean (SD)                             78 (10)                                       77 (9.9)                      79 (11)                              78 (10)
                                                                                                                                                           
  **Blood and urine test results**                                                                                                                         
    **eGFR, ml/min/1.73 m^2^**                                                                                                                             
      \>60, *n* (%)                       396 (46.0)                                    84 (25.7)                     135 (52.5)                           177 (63.9)
      ≤60, *n* (%)                        465 (54.0)                                    243 (74.3)                    122 (47.5)                           100 (36.1)
      Median (IQR)                        59 (46 to 69)                                 50 (35 to 61)                 61 (48 to 76)                        63 (57 to 74)
      Mean (SD)                           58.0 (18.4)                                   48.9 (17.1)                   61.4 (18.7)                          65.7 (14.6)
    **ACR, mg/mmol, *N* (%)**             **774 (89.9)**                                **288 (88.1)**                **239 (93.0)**                       **247 (89.2)**
      \<3.0, *n* (%)                      489 (63.2)                                    194 (67.4)                    116 (48.5)                           214 (86.6)
      ≥3.0, *n* (%)                       285 (36.8)                                    94 (32.6)                     123 (51.5)                           148 (59.9)
      Median (IQR)                        2.0 (0.9 to 4.8)                              1.6 (0.6 to 4.2)              3.1 (1.3 to 7.5)                     1.6 (0.9 to 3.4)
      Mean (SD)                           5.2 (11.4)                                    5.1 (12.3)                    7.8 (14.6)                           2.8 (3.6)
                                                                                                                                                           
  **Questionnaires, *n* completed (%)**                                                                                                                    
    Quality of life                       859 (99.8)                                    327 (100.0)                   256 (99.6)                           276 (99.6)
    Diet                                  310 (36.0)                                    148 (45.3)                    79 (30.7)                            83 (30.0)
    Physical activity                     736 (85.5)                                    318 (97.2)                    205 (79.8)                           213 (76.9)
    Cognitive assessment                  625 (72.6)                                    249 (76.1)                    182 (70.8)                           194 (70.0)

Data missing for one patient. ACR = albumin:creatinine ratio. BMI = body mass index. CI = confidence interval. CKD = chronic kidney disease. eGFR = estimated glomerular filtration rate. IQR = interquartile range. SD = standard deviation.

###### 

Patient demographics stratified by CKD stage, *N* = 860[^a^](#tfn2){ref-type="table-fn"}

  **Characteristics**            **Normal kidney function (*N* = 258)**   **CKD stage 1 (*N* = 34)**   **CKD stage 2 (*N*= 122)**   **CKD stage 3a (*N*= 246)**                   **CKD stage 3b (*N* = 133)**   **CKD stage 4 (*N*= 67)**
  ------------------------------ ---------------------------------------- ---------------------------- ---------------------------- --------------------------------------------- ------------------------------ ---------------------------
  Mean age, years (SD)           72.6 (6.7)                               70.6 (4.8)                   73.6 (7.3)                   74.5 (6.3)                                    75.7 (7.2)                     76.3 (7.2)
  Female, *n* (%)                158 (61.2)                               13 (38.2)                    54 (44.3)                    132 (53.7)                                    76 (57.1)                      34 (50.7)
  Weight, kg (SD)                76.6 (16.9)                              79.9 (23.4)                  76.6 (17.2)                  78.6 (17.2)                                   79.1 (16.5)                    80.8 (15.1)
  Height, cm (SD)                167.0 (10.7)                             169.1 (9.3)                  166.8 (10.4)                 166.8 (10.5)                                  167.0 (9.7)                    167.2 (12.1)
  Waist circumference, cm (SD)   95.5 (15.3)                              97.3 (18.5)                  95.1 (15.4)                  97.5 (13.7)                                   98.6 (13.3)                    100.8 (12.7)
  Hip circumference, cm (SD)     105.8 (11.1)                             102.4 (10.5)                 104.1 (9.7)                  107.0 (9.9)                                   108.4 (11.1)                   109.2 (11.3)
  BMI, kg/m^2^ (SD)              27.4 (5.8)                               27.6 (6.6)                   27.7 (7.7)                   28.4 (9.1)                                    28.3 (5.4)                     29.3 (8.3)
                                                                                                                                                                                                                 
  **Ethnicity, *n* (%)**                                                                                                                                                                                         
    White                        254 (98.4)                               34 (100.0)                   120 (98.4)                   239 (97.2)[^b^](#tfn3){ref-type="table-fn"}   132 (99.2)                     66 (98.5)
    Other                        4 (1.6)                                  --                           2 (1.6)                      6 (2.4)                                       1 (0.8)                        1 (1.5)

One participant with CKD stage 5 not included.

Data missing for one patient. BMI = body mass index. CKD = chronic kidney disease. SD = standard deviation.

Stratification by stage of CKD using eGFR and ACR shows that 258 participants (30.0%) met the KDIGO definition of normal kidney function (eGFR ≥60 ml/min/1.73 m^2^ and ACR \<3 mg/mmol),^[@b8]^ 34 participants (4.0%) had CKD stage 1, 122 (14.2%) had CKD stage 2, 246 (28.6%) had CKD stage 3a, 133 (15.5%) had CKD stage 3b, 67 (7.8%) had CKD stage 4, and one (0.12%) had stage 5 CKD. Over half of the CKD cohort fell into CKD stages 3--5, which gave a prevalence of CKD stages 3--5 of 13.9% (447/3207) from the full population screened (see [Table 2](#table2){ref-type="table"} and Supplementary Table S1). Results were similar in sensitivity analyses where approximations were made (see Supplementary Table S2 for details).

CKD stage of participants stratified by entry to the CKD cohort is shown in [Figure 3](#fig3){ref-type="fig"} and Supplementary Table S3. Sixty-five participants with previously diagnosed CKD (20%, *N* = 327), 58 with newly diagnosed CKD (23%, *N* = 257), and 135 with borderline/transient decreased renal function (49%, *N* = 277) were classified as having normal kidney function (by KDIGO definition)^[@b8]^ at their baseline visit. Stage of CKD and eGFR calculated using the CKD-EPI equation is shown in Supplementary Table S4 and S5, and Supplementary Figure S1. Overall, there were more people with CKD stages 2 and 4 and fewer people with CKD stages 1, 3a, and 3b compared with CKD stage calculated using the MDRD equation. More people had reduced eGFR (\<60 ml/min/1.73 m^2^) using MDRD than with CKD-EPI in the 60--75-year age group, and more had reduced eGFR using CKD-EPI in the ≥80-year age group ([Figure 4](#fig4){ref-type="fig"}).

![***Chronic kidney disease (CKD) stage of participants stratified by entry to the cohort calculated using the Modification of Diet in Renal Disease (MDRD) equation.***](bjgpApr-2020-70-693-e285-OA-3){#fig3}

![***Participant eGFR using the Modification of Diet in Renal Disease (MDRD) equation and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation stratified by age. CKD = chronic kidney disease. eGFR = estimated glomerular filtration rate.***](bjgpApr-2020-70-693-e285-OA-4){#fig4}

DISCUSSION
==========

Summary
-------

This large-scale screening study from UK primary care offers a prevalence estimate of 18.2% (95% CI = 16.9 to 19.6) for CKD stages 1--5 in people aged ≥60 years and has found that 8.0% of this population had CKD that was previously undiagnosed. More than half (51.3%) of those with only a single positive CKD screening test (borderline/transient decreased renal function group), thus not meeting the diagnostic criteria for CKD, were classified into CKD stages 1--4 at the baseline assessment. Providing the baseline samples were taken a minimum of 12 weeks from their previous positive test, these participants now technically meet the diagnostic criteria for CKD.^[@b8]^

Strengths and limitations
-------------------------

This study is methodologically strong, using both MDRD and CKD-EPI equations to calculate eGFR and including urinary ACR to estimate CKD prevalence unlike many previous registry studies, which have had less urinary ACR data available. This study reports CKD prevalence by stage of CKD and found that more participants were classified into CKD stage 3a than any other CKD stage. Furthermore, over one-fifth (21.1%) of those with existing CKD were classed as having normal renal function from analysis of blood and urine samples taken at their baseline visit. This highlights how the variability in both eGFR and ACR can result in some participants, who had previously met the diagnostic criteria for CKD, falling into the normal kidney function range on repeat testing. This suggests that there is potential for disease misclassification, which could be an artefact of the interval between screening visits.^[@b21]^ As more laboratories move away from MDRD to use other equations for estimating GFR,^[@b7],[@b22],[@b23]^ the CKD stage for some individuals may change, and others may no longer meet criteria for diagnosis.^[@b22]^ Findings from this study corroborate those from other studies, in that moving to CKD-EPI will result in a greater proportion of people aged \>75 years having decreased eGFR compared with MDRD and fewer people aged \<75 years with reduced eGFR.^[@b14],[@b24]^ This analysis has also quantified how moving to the CKD-EPI equation may lead to classification into a different CKD stage for some participants.

There are some limitations to this study. It is possible that people who were aware that they had CKD were more likely to agree to participate in the study, which may have led to an overestimation in the prevalence of CKD in this cohort. Over 98% of the OxRen cohort were white, which is a higher proportion than the 95% white ethnicity reported in the general UK population aged ≥60 years.^[@b25]^ This is also higher than the rest of Oxfordshire where 92% of the population is white.^[@b26]^ The low percentage of ethnic minority participants in the cohort may have affected the CKD prevalence. Some reports suggest that South Asians have a lower prevalence of CKD when compared with white individuals after adjustment for age and sex.^[@b27]^ However, Asian and African and Caribbean populations with diabetes have been reported to show the most rapid decline in renal function^[@b28]^ and African and Caribbean populations have a high incidence of ESRD.^[@b28],[@b29]^ There were relatively low numbers of people with CKD stage 1, 4, and 5 in the present cohort, but these low numbers are also seen in the general population.^[@b2],[@b30]^

Despite efforts to recruit GP practices in Oxfordshire with different indexes of deprivation profiles to ensure comparability with the general UK population, recruitment took place over a single UK county, which may not be fully representative of the general UK population. The proportion of people with university education or above is 18% in the UK population aged \>65 years^[@b31]^ compared with 24% in the OxRen population. However, younger age groups in the general population have a greater proportion achieving the highest level of educational attainment and fewer people leaving school with no qualifications compared with older age groups.^[@b31]^ As these populations age, findings from the cohort may be generalisable to these age groups after accounting for lifestyle factors. Both lower education and socioeconomic status are associated with higher prevalence of CKD.^[@b32]^

Comparison with existing literature
-----------------------------------

UK prevalence of CKD stages 1--5 in people aged 65--74 years has been reported to be 19%,^[@b2]^ which is similar to prevalence found in the OxRen cohort. For those \>75 years of age, prevalence reaches 46%.^[@b2]^ A systematic review and meta-analysis reporting global prevalence of CKD stratified by age found a prevalence of CKD stages 1--5 of nearly 28% in populations with a mean age of \>60 years and around 34% in those with a mean age of 70 years.^[@b30]^ These are higher than the prevalence of 18% in the present study, which may reflect differences in the diagnostic criteria used, or prevalence in different ethnic groups and socio-economic status.^[@b32]^ Other English data suggest that prevalence of CKD stages 3--5 is 12.0--14.5% in those aged 65--74 years.^[@b2],[@b33]^ This is similar to the 13.9% (95% CI = 12.8 to 15.1) found in the OxRen cohort despite these surveys using a single eGFR test to classify CKD, which has been shown to overestimate CKD.^[@b10],[@b22]^ Internationally, most prevalence estimates in similar age groups are only based on a single test result.^[@b11],[@b34],[@b35]^ In Europe, prevalence differs between countries and ranges from 24% in Norway to 41% in Germany.^[@b11]^ In the US, prevalence of stages 3--4 is 23%,^[@b34]^ and stages 1--5 of 34%.^[@b35]^

A recently published analysis of participants in the OxRen cohort^[@b22]^ found that using a single screening test to diagnose CKD would result in around 25% over diagnosis because of variability in ACR and eGFR. The results from laboratory analyses at participants' baseline visit show that some participants' CKD stage can revert to normal kidney function despite a recent diagnosis. This was observed in 21% of OxRen participants who had received a CKD diagnosis but tested as normal kidney function, based on samples taken during their baseline visit. A combination of analytical and biological variability may have contributed to this.^[@b36]^ These numbers are consistent with a previous report that found CKD remission rates of 20--30% in follow-up visits in primary care populations with CKD.^[@b37]^

Implications for research and practice
--------------------------------------

This study has found that 8.0% of participants aged ≥60 years had undiagnosed CKD, equating to 44.0% of people living with CKD in this population, and would have remained undiagnosed without screening. This suggests that the early stages of CKD (stages 1--3b) may be under-reported in the literature as many people are unaware that they have the condition.^[@b10],[@b38]^ In the UK, some of these people will be picked up in the NHS Health Check Programme ([www.healthcheck.nhs.uk](www.healthcheck.nhs.uk)), which is a 5-yearly free check-up available for adults in the UK aged 40--74 years. However, only 43% of those invited for an NHS Health Check are reported to attend,^[@b39]^ and it is likely that many non-attenders will be those most at risk.^[@b40]^

OxRen provides an estimate of undiagnosed CKD in the UK population aged ≥60 years, including screen-detected rates, and will provide future estimates of incidence. Follow-up will provide evidence on the progression of CKD, and, if progression occurs, identify groups that are most likely to progress, which will make it possible to explore associations with comorbidities and treatments.
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